Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar 2025 revenue falls 2% to $719.9 million; GAAP EPS drops to $2.03

Negative Impact 3 of 5 earnings Written later

Amphastar reported fourth-quarter and full-year 2025 results on February 26, 2026. Revenue, GAAP net income and diluted EPS declined from 2024 in both periods, and the release does not include financial guidance for 2026. Full-year results include a $23.1 million litigation provision, and glucagon sales fell 45% in the fourth quarter on lower average selling prices and unit volumes.

Key points

  • Q4 2025 net revenues were $183.1 million, down 2% from $186.5 million in Q4 2024
  • Q4 GAAP diluted EPS was $0.51 vs. $0.74; adjusted non-GAAP diluted EPS was $0.73 vs. $0.92
  • Full-year 2025 net revenues were $719.9 million vs. $732.0 million; GAAP diluted EPS was $2.03 vs. $3.06
  • BAQSIMI sales rose 46% to $185.4 million for the full year, while glucagon sales fell 36% to $69.1 million

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECFeb 26, 2026, 4:24 PM ET
Accession number0001297184-26-000007

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.